Bradsaude SA (SAUD3) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Bradsaude SA stock BRL 6.04, price BRL 15.07, that is 60.0% below the price, quality 68 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
60‑month range R$6.26 – R$16.55 · fair‑value band R$4.05 – R$7.84 · the R$15.07 price screens above the R$6.04 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.
Follow Bradsaude in your weekly email
Every Wednesday you see whether Bradsaude is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Bradsaúde S.A. provides private dental care plans in Brazil. The company operates through Corporate, Small and Medium-Sized Enterprise (SME), Individual, and Other segments. The company manages and sells dental care plans to corporations and/or individuals.
Show moreShow less
It is also involved in commercial advisory, consulting, and business management services; develops and licenses software programs; wholesale and retail trade of products and equipment, sanitizers, drugs, medicines, pharmaceutical inputs, and related items; provision of storage, loading, organization, tidying, custody of goods, technical, and administrative programming services, as well as general management of assets and business.
In addition, the company engages in integrating technologies to develop dental solutions; and provide specialized services related to accidents and illnesses, besides actuarial, financial, administrative, and commercial and risk management services.
The company was formerly known as Odontoprev S.A. and changed its name to Bradsaúde S.A. in April 2026. Bradsaúde S.A. was founded in 1987 and is headquartered in Barueri, Brazil. Bradsaúde S.A. operates as a subsidiary of Bradesco Saúde S.A.
Stock analysis
Bradsaude SA (SAUD3) currently trades at R$15.07, while our model-based Fair Value estimate is R$6.04, 60% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of R$4.12 per share, and 0 of the 26 models we run sit above the R$15.07 price.
Bear case: the Economic Profit group reads lowest at R$1.51, and 26 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: R$4.05 (bear) to R$7.84 (bull), the price of R$15.07 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 68/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Bradsaude SA reported revenue of R$2.4B in FY2025 versus R$1.8B in FY2021, a compound +7.0%/yr. Reported net income was R$583M in FY2025, compounding +11.2%/yr from FY2021.
Key figures
Market cap R$44.1B (≈ $8.0B) Mid · P/E ratio 13.3 · P/S ratio 3.21 · EPS (TTM) R$1.13 · Dividend yield 2.5% · Net margin 24.1% · Return on equity 20.0% · Return on assets (EBIT) 30.5% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 68 out of 100 (low confidence).
What moves the price
The share trades about 9% below its 52-week high and 45% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −60%, SAUD3 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (R$0.0800 to R$5.57). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
BearR$4.05Fair Value R$6.04BullR$7.84
Price R$15.07 · Downside -60.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (R$0.6488 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCFR$2.09R$3.27R$4.9878
Growth DCFR$2.07R$3.14R$4.5875
Residual IncomeR$0.9600R$1.18R$1.9574
All 26 models by family
DCF Models
FCF DCFR$2.09R$3.27R$4.9878
Owner EarningsR$2.92R$4.58R$6.9673
5Y Revenue ExitR$1.84R$2.99R$4.4969
5Y EBITDA ExitR$2.95R$5.19R$7.9471
5Y P/E ExitR$2.62R$4.55R$6.6867
10Y Revenue ExitR$1.87R$2.90R$4.3764
10Y EBITDA ExitR$2.57R$4.33R$6.8964
10Y P/E ExitR$2.38R$3.91R$5.9761
Earnings-Based
Graham-DoddR$1.36R$5.57R$7.5964
Lynch FVR$1.40R$2.00R$2.6061
PEG = 1.0R$1.40R$2.00R$2.6057
EPVR$1.40R$1.58R$1.7370
Dividend Discount
Gordon GGMR$1.71R$3.03R$4.1068
DDM Multi-StageR$1.71R$2.79R$3.2467
Multiples
P/E MultipleR$3.29R$4.38R$5.4863
P/S MultipleR$2.17R$2.90R$3.6258
P/B MultipleR$0.3900R$0.5100R$0.640055
EV/EBITR$3.36R$4.48R$5.6063
EV/EBITDAR$3.88R$5.17R$6.4764
EV/RevenueR$1.74R$2.48R$3.2351
Asset-Based
NCAV (Graham)R$0.0600R$0.0800R$0.110052
Growth DCF
Growth DCFR$2.07R$3.14R$4.5875
Rev-Margin DCFR$1.84R$2.98R$4.4069
Economic Profit
Residual IncomeR$0.9600R$1.18R$1.9574
ROIC CompounderR$1.50R$1.83R$2.1870
Growth Earnings
Growth-Adj P/ER$2.48R$3.55R$4.6167
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.77/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+6.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.5%
Start year 2020 (pandemic). Over 10 years: +6.8% a year
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in BRL ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in BRL: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+14.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+11.6%
Dividend (yield on the price)2.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.11.6% vs 11.5%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.29% → 32%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+39.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Brazil: IMF forecast 3.3% a year to 2030, 5.4% from 2016 to 2025) that is about +35.5% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Healthcare Plans” was too small, so the broader sector is used.)Health Care · 2277 stocks
Beats the sector median on 10/14 measures
Overall it ranks above its sector peers.
Valuation
Quality Score68 · Top 25%
Fair Value upside−60.0% · Below median
Profitability
Return on equity (12 months)20.0% · Top 25%
Return on assets29.9% · Top 25%
Net margin (12 months)9.1% · Above median
Operating margin (12 months)16.5% · Above median
Growth and dividend
Revenue growth (quarter YoY)18.8% · Above median
Dividend yield (12 months)2.5% · Above median
Valuation Multiplesvs Health Care median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Bradsaude SA Fair Value". https://www.fairvalue-calculator.com/stock/SAUD3
Frequently asked questions
Is Bradsaude SA (SAUD3) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of R$6.04 versus a price of R$15.07, about 60% lower (overvalued).
What is the fair value of SAUD3?
Our model-based fair value for Bradsaude SA is R$6.04 (as of Nov 4, 2026), built from audited fundamentals. The current price: R$15.07.
What is the quality score of SAUD3?
Bradsaude SA has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bradsaude SA (SAUD3)?
Our model-based price target is the fair value of R$6.04 (as of Nov 4, 2026) from 26 valuation models. Cautious scenario R$4.05, optimistic scenario R$7.84. It is a calculation from audited fundamentals, not an analyst target.
What is the Bradsaude SA stock forecast for 2026?
Our models put fair value at R$6.04, about 60% lower versus a price of R$15.07 (overvalued). Cautious scenario R$4.05, optimistic scenario R$7.84. The calculation is refreshed regularly with new filings.
Does Bradsaude SA pay a dividend?
Bradsaude SA currently shows a dividend yield of 2.46% relative to its recent price (as of Nov 4, 2026).
How much is the dividend of Bradsaude SA (SAUD3) and when is the ex-dividend date?
Bradsaude SA pays a dividend of R$0.371 per share a year, a dividend yield of 2.5%. The last ex-dividend date was Nov 3, 2026. A dividend has been paid every year since at least 2008. The payout ratio is 32.8% of earnings. Free cash flow covers the dividend 0.54 times. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What growth is priced into Bradsaude SA (SAUD3)?
For today's price to be fair in a discounted-cash-flow model, Bradsaude SA would have to grow free cash flow by +39.9 % per year for five years (discount rate 11.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +6.5 % per year. As of Nov 4, 2026.
What discount rate (WACC) does the fair value of SAUD3 use?
Our models discount Bradsaude SA at 11.4 %: a base by market capitalisation (mid), damped by beta 0.57, country premium for Brazil. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Bradsaude SA that is +39.9 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.4 %) and the same formula as our fair value.
How much growth has Bradsaude SA (SAUD3) delivered so far?
Over the past 5 years revenue at Bradsaude SA grew +6.5 % a year. The price currently implies free-cash-flow growth of +39.9 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Bradsaude SA (SAUD3) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into Bradsaude SA (+39.9 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Bradsaude SA (SAUD3)?
The free-cash-flow yield on the price is 1.34 %: that much free cash flow Bradsaude SA produces per unit of market value. When it exceeds the discount rate of our models (11.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Bradsaude SA (SAUD3)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bradsaude SA it is R$6.04 per share (as of Nov 4, 2026), against a price of R$15.07. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Bradsaude SA stock overvalued or undervalued in 2026?
As of Nov 4, 2026, SAUD3 trades above its calculated fair value: price R$15.07, fair value R$6.04, a gap of about −60% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SAUD3?
No. The price is what the market pays today (R$15.07); the fair value is what the company's own numbers justify (R$6.04). For Bradsaude SA the two are R$9.04 per share apart. That gap is exactly why we show both numbers side by side.
How much is Bradsaude SA worth?
The market values Bradsaude SA at about R$44.1B (market capitalisation, as of Nov 4, 2026). Per share that is R$15.07; our models calculate a fair value of R$6.04 per share.
What do the bullish and bearish scenarios say about SAUD3?
Our models span a range for Bradsaude SA: cautious scenario R$4.05, base R$6.04, optimistic R$7.84 per share (as of Nov 4, 2026, price R$15.07). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SAUD3?
Bradsaude SA trades at a price-to-earnings ratio of 13.3 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of R$6.04 is built from several models across several years. Other multiples: PEG 1.7, P/B 34.4, P/S 1.9, EV/EBITDA 11.7.
What is the PEG ratio of SAUD3?
The PEG ratio of Bradsaude SA is 1.70 (P/E divided by earnings growth, as of Nov 4, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Bradsaude SA (SAUD3)?
Balance-sheet figures for Bradsaude SA (as of Nov 4, 2026): return on equity 20.0%. They feed the Quality Score of 68/100, which measures business quality independently of the share price.
How far is SAUD3 from its 52-week high?
Bradsaude SA trades at R$15.07, about 9% below its 52-week high of R$16.55 and 45% above the low of R$10.39 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of R$6.04 is for.
Which stocks are comparable to Bradsaude SA?
From the same area (Healthcare) we also value UnitedHealth Group, CVS Health Corporation, Elevance Health, Inc, The Cigna Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bradsaude SA stock attractive at the current price?
The data as of Nov 4, 2026: price R$15.07, calculated fair value R$6.04 (−60%), Quality Score 68/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SAUD3 calculated?
We run Bradsaude SA through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of R$6.04 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Bradsaude SA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bradsaude SA (SAUD3)?
The closing price on Nov 6, 2026 was R$15.07. Our model-based fair value is R$6.04, about 60% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bradsaude SA right now?
The price sits above even our optimistic bull case (R$7.84). The favourable scenario is already priced in. Solid but not exceptional quality (68/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (R$4.05 to R$7.84) leaves room in how you read the outcome.
Where does the earnings growth of Bradsaude SA (SAUD3) come from?
Earnings per share at Bradsaude SA grew +12.0 % a year from 2014 to 2025. Broken into its drivers: revenue per share +7.7 %, EBIT margin +3.3 %, tax rate +0.3 %, residual (interest, one-offs) +0.5 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Bradsaude SA
How large is the market capitalisation of Bradsaude SA (SAUD3)?
The market capitalisation of Bradsaude SA is R$44.1B (≈ $8.0B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bradsaude SA (SAUD3)?
The price-to-sales ratio of Bradsaude SA is 3.21 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Bradsaude SA (SAUD3)?
Earnings per share at Bradsaude SA are R$1.13 (price ÷ EPS = P/E 13.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Bradsaude SA (SAUD3)?
The dividend yield of Bradsaude SA is 2.5% (payout 32.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Bradsaude SA (SAUD3)?
The net margin of Bradsaude SA is 24.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Bradsaude SA (SAUD3)?
The return on equity (ROE) of Bradsaude SA is 20.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bradsaude SA (SAUD3)?
On an EBIT basis the return on assets of Bradsaude SA is 30.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bradsaude SA (SAUD3)?
The operating margin of Bradsaude SA is 16.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bradsaude SA (SAUD3)?
Revenue at Bradsaude SA is growing +18.8% versus a year earlier (3y avg +9.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Bradsaude SA (SAUD3)?
Earnings per share at Bradsaude SA are growing +54.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Bradsaude SA (SAUD3) carry?
The net debt of Bradsaude SA is R$874K (fiscal year 2025, ≈ 0.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Bradsaude SA in the live analysis
One click puts Bradsaude SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 4, 2026